Romosozumab

Status:

Red

Decision Date:

June 2022

Comments

RED: NICE TA791 - Romosozumab for treating severe osteoporosis. ICB commissioned. 

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating

search again